INHIBITOR Therapeutics Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • INTI

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.11
  • (As of Friday Closing)

INHIBITOR Therapeutics General Information

Description

Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Contact Information

Website
www.inhibitortx.com
Formerly Known As
Hedgepath Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Stock Exchange
PINX
Primary Office
  • 324 South Hyde Park Avenue
  • Suite 350
  • Tampa, FL 33606
  • United States
+1 (813) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

INHIBITOR Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.11 $0.09 $0.01 - $0.30 $18.6M 172M 28K $0.02

INHIBITOR Therapeutics Financials Summary

In Thousands,
USD 		TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (812) 41,534 60,573 17,024
Revenue 0 0 0 0
EBITDA 10,287 12,185 (284) (1,059)
Net Income 10,502 12,106 (299) (1,058)
Total Assets 9,608 11,975 59 132
Total Debt 0 411 231 97
Public Fundamental Data provided by Morningstar, Inc. disclaimer

INHIBITOR Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore INHIBITOR Therapeutics‘s full profile, request access.

Request a free trial

INHIBITOR Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies f
Pharmaceuticals
Tampa, FL
6 As of 2022
0000
000000000 0000

000000

tion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000 000000000
Torrance, CA
00 As of 0000
000.00
000000000 - 000.00

000000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
000000000000000
Dallas, TX
00 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

INHIBITOR Therapeutics Competitors (70)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Emmaus Life Sciences Formerly VC-backed Torrance, CA 00 000.00 000000000 - 000.00
0000000 0000000000 Formerly VC-backed Dallas, TX 00 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Newark, CA 00 00000 00000000 00000
00000000 Formerly VC-backed Needham, MA 00 00000 000000000 00000
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
You’re viewing 5 of 70 competitors. Get the full list »

INHIBITOR Therapeutics Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

INHIBITOR Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190365742-A1 Azole treatment regimen with reduced hepatotoxicity Inactive 30-May-2018 0000000000

INHIBITOR Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Garrison Hasara Chief Financial Officer, Treasurer, Corporate Secretary, Chief Compliance Officer
You’re viewing 1 of 3 executive team members. Get the full list »

INHIBITOR Therapeutics Board Members (2)

Name Representing Role Since
000000 0'00000 INHIBITOR Therapeutics Board Member 000 0000
000000 00000 00. INHIBITOR Therapeutics Board Member 000 0000
To view INHIBITOR Therapeutics’s complete board members history, request access »

INHIBITOR Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

INHIBITOR Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore INHIBITOR Therapeutics‘s full profile, request access.

Request a free trial

INHIBITOR Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Commonwealth Biotechnologies 09-Aug-2013 0000000000 Other Healthcare Services
To view INHIBITOR Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial